Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01318499 · ClinicalTrials.gov registry record · Phase 2
Nepafenac 0.3% Two Study
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,342
- Enrollment target
NCT01318499 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 1,342 participants.
The verdict
NCT01318499, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,342 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
Interventions
- DRUG Nepafenac Ophthalmic Suspension, 0.3%
- DRUG Nepafenac Ophthalmic Suspension, 0.1%
- OTHER Nepafenac Vehicle 0.3%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,342 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01318499
The ClinicalTrials.gov registry entry for NCT01318499 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nepafenac Ophthalmic Suspension, 0.3% is the first listed.
NCT01318499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01318499 about?
NCT01318499 is a clinical study titled "Nepafenac 0.3% Two Study". The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
What is the current status of trial NCT01318499?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,342 participants. The study started on 2011-03. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01318499?
The interventions under investigation include: Nepafenac Ophthalmic Suspension, 0.3% (DRUG), Nepafenac Ophthalmic Suspension, 0.1% (DRUG), Nepafenac Vehicle 0.3% (OTHER).
Who is sponsoring clinical trial NCT01318499?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.